nonproprietary name


Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia.

non·pro·pri·e·tar·y name

(non'prō-prī'ĕ-tār'ē nām),
A short name (often called a generic name) of a chemical, drug, or other substance that is not subject to trademark (proprietary) rights but is, in contrast to a trivial name, recognized or recommended by government agencies (for example, U.S. Food and Drug Administration) and by quasiofficial organizations (for example, U.S. Adopted Names Council) for general public use. Like a proprietary name, it is almost always a coined designation derived without the use of set criteria. Compare: trivial name, proprietary name, semisystematic name, systematic name.

nonproprietary name

(nŏn′prə-prī′ĭ-tĕr′ē)
n.
The chemical or generic name of a drug, chemical, or device, as distinguished from a brand name or trademark.

non·pro·pri·e·tar·y name

(non'prŏ-prī'ĕ-tar-ē nām)
A short name (often called a generic name) of a chemical, drug, or other substance that is not subject to trademark (proprietary) rights but is, in contrast to a trivial name, recognized or recommended by government agencies (e.g., The U.S. Food and Drug Administration) and by quasiofficial organizations (e.g., U.S. Adopted Names Council) for general public use.
Compare: trivial name, proprietary name, systematic name

non·pro·pri·e·tar·y name

(non'prŏ-prī'ĕ-tar-ē nām)
Short name (often called a generic name) of a chemical, drug, or other substance not subject to trademark (proprietary) rights but is, in contrast to a trivial name, recognized or recommended by government agencies (e.g., U.S. Food and Drug Administration) and by quasiofficial organizations (e.g., U.S. Adopted Names Council) for general public use. Like a proprietary name, it is almost always a coined designation derived without set criteria.
References in periodicals archive ?
Varying nonproprietary names will imply none-too-subtly that biosimilar medications are clinically different, despite the BPCIA's stern mandate that all biosimilars must contain no clinically meaningful difference from corresponding original biologics.
M2 PHARMA-March 23, 2012-Endocyte Inc gets USAN & WHO approval for nonproprietary names of vintafolide for EC145 and EC20(C)2012 M2 COMMUNICATIONS
WASHINGTON -- More than 30 organizations have signed a letter calling on the Food and Drug Administration to require biologies and biosimilars to have the same International Nonproprietary Name (INN), a practice currently in use in Europe and other markets.
Food, Drug and Cosmetic Act--when compendial monographs are published and made official--to specify the nonproprietary name of drug substances and drug products, as well as to set quality standards.
In another health care issue, the two retail pharmacy associations, as well as the American Pharmacists Association, dispatched a letter to the World Health Organization regarding the issue of naming biosimilars through an individual nonproprietary name (INN) qualifier.
The council--sponsored by such groups as the American Medical Association, American Pharmacists Association and the United States Pharmacopeial Convention--works closely with WHO's international nonproprietary name program.
Upon receiving feedback from the USAN Council, which is expected later this year, Genprex will submit its non-proprietary drug name selections to the World Health Organization for International Nonproprietary Names status.
Additionally, the United States Adopted Names Council (USAN), in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has adopted nipocalimab as the nonproprietary (generic) drug name for M281.